Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: Behind the 'breakthrough'

Evidence-Based Medicine

Volumn 21, Issue 3, 2016, Pages 83-86

  Mayer, Martin ^a,b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b VIDANT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DORNASE ALFA; IVACAFTOR PLUS LUMACAFTOR; TOBRAMYCIN; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; DRUG COMBINATION; LUMACAFTOR, IVACAFTOR DRUG COMBINATION; QUINOLONE DERIVATIVE;

BODY MASS; CHEST TIGHTNESS; CONTROLLED CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH CARE AVAILABILITY; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; NAUSEA; PATIENT DECISION MAKING; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; DISEASE COURSE; DRUG APPROVAL; DRUG COMBINATION; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; LUNG; PATHOPHYSIOLOGY; QUESTIONNAIRE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; BODY MASS INDEX; CYSTIC FIBROSIS; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DRUG APPROVAL; DRUG COMBINATIONS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG; QUINOLONES; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84954527069     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebmed-2015-110325     Document Type: Review

References (18)

1. FDA News Release: FDA approves new treatment for cystic fibrosis. Updated 8 July 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm (accessed 17 Jul 2015).
2. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor- Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220-31. [See also the accompanying protocol and appendix documents, available in full online with the electronic version of this article.].
3. Pulmonary-Allergy Drugs Advisory Committee. FDA briefing document, NDA# 206038: for lumacaftor/ivacaftor combination oral tablets for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 12 May 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM446193.pdf (accessed 20 May 2015).
4. Vertex. Sponsor briefing document for the FDA Pulmonary- Allergy Drugs Advisory Committee: Orkambi (Lumacaftor/ Ivacaftor) for the treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene: NDA 206038. 6 April 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM446195.pdf (accessed 20 May 2015).
5. FDA presentation slides for the May 12, 2015 meeting of the Pulmonary-Allergy Drugs Advisory Committee. 12 May 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM447292.pdf. (accessed 20 May 2015).
6. Vertex presentation slides for the May 12, 2015 meeting of the Pulmonary-Allergy Drugs Advisory Committee. 12 May 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM447293.pdf. (accessed 20 May 2015).
7. Weisman R. FDA clears Vertex's new treatment for cystic fibrosis. The Boston Globe. 2 July 2015. https://www.bostonglobe.com/business/2015/07/02/fda-approves-vertexcystic-fibrosis-medicine/jzn9eCDenCq4rEI671mDOM/story.html# (accessed 17 Jul 2015).
8. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-18.
9. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
10. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
11. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
12. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
13. van Gool K, Norman R, Delatycki MB, et al. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health 2013;16:345-55.
14. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-96.
15. Gu Y, García-Pérez S, Massie J, et al. Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. Eur J Health Econ 2015;16:709-17.
16. Jones AM, Barry PJ. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax 2015;70:615-16.
17. Bilton D. A new chapter in therapy for cystic fibrosis. Lancet Respir Med 2015;3:e20.
18. Sears T. 'It's a game changer,' new drug to treat cystic fibrosis holds promise. CBS 6 News. 7 July 2015. http://wtvr.com/2015/07/07/its-a-game-changer-new-drug-to-treat-cystic-fibrosisholds-promise/ (accessed 17 Jul 2015).